NKTX · Nkarta Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 1.53 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 7 / 20 / 33 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 16 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -27.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +58.3% |
| Market cap (USD) | $212.4M |